select a format

Single User License
USD 2000 INR 128140
Site License
USD 4000 INR 256280
Corporate User License
USD 6000 INR 384420

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Major Depressive Disorder-Pipeline Review, H2 2015

Major Depressive Disorder-Pipeline Review, H2 2015


  • Products Id :- GMDHC7217IDB
  • |
  • Pages: 212
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Major Depressive Disorder-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Major Depressive Disorder-Pipeline Review, H2 2015', provides an overview of the Major Depressive Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Major Depressive Disorder Overview 8

Therapeutics Development 9

Pipeline Products for Major Depressive Disorder-Overview 9

Pipeline Products for Major Depressive Disorder-Comparative Analysis 10

Major Depressive Disorder-Therapeutics under Development by Companies 11

Major Depressive Disorder-Therapeutics under Investigation by Universities/Institutes 15

Major Depressive Disorder-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Major Depressive Disorder-Products under Development by Companies 19

Major Depressive Disorder-Products under Investigation by Universities/Institutes 23

Major Depressive Disorder-Companies Involved in Therapeutics Development 24

Aequus Pharmaceuticals Inc. 24

Alkermes Plc 25

Allergan Plc 26

Angelini Group 27

Azevan Pharmaceuticals, Inc. 28

BioCrea GmbH 29

Bristol-Myers Squibb Company 30

Cerecor Inc. 31

e-Therapeutics Plc 32

Eli Lilly and Company 33

F. Hoffmann-La Roche Ltd. 34

GlaxoSmithKline Plc 35

H. Lundbeck A/S 36

Hua Medicine Ltd. 37

Intra-Cellular Therapies, Inc. 38

Jiangsu Hansoh Pharmaceutical Co., Ltd. 39

Johnson & Johnson 40

Lead Discovery Center GmbH 41

Luye Pharma Group Ltd. 42

Mapreg S.A.S. 43

Methylation Sciences Inc. 44

miCure Therapeutics Ltd. 45

Mitsubishi Tanabe Pharma Corporation 46

Naurex, Inc. 47

Neuralstem, Inc. 48

nLife Therapeutics, S.L. 49

Otsuka Holdings Co., Ltd. 50

Pherin Pharmaceuticals, Inc. 51

Reviva Pharmaceuticals Inc. 52

Richter Gedeon Nyrt. 53

Saniona AB 54

Sumitomo Dainippon Pharma Co., Ltd. 55

Sunovion Pharmaceuticals Inc. 56

Suven Life Sciences Ltd. 57

VistaGen Therapeutics, Inc. 58

Major Depressive Disorder-Therapeutics Assessment 59

Assessment by Monotherapy Products 59

Assessment by Combination Products 60

Assessment by Target 61

Assessment by Mechanism of Action 64

Assessment by Route of Administration 67

Assessment by Molecule Type 69

Drug Profiles 71

(aripiprazole + sertraline)-Drug Profile 71

(samidorphan + buprenorphine hydrochloride)-Drug Profile 72

AN-788-Drug Profile 74

aripiprazole-Drug Profile 75

AV-101-Drug Profile 76

AVP-786-Drug Profile 78

basimglurant-Drug Profile 80

brexpiprazole-Drug Profile 82

bupropion hydrochloride ER-Drug Profile 85

cariprazine-Drug Profile 86

CERC-301-Drug Profile 89

CERC-501-Drug Profile 90

desvenlafaxine succinate SR-Drug Profile 91

edivoxetine hydrochloride-Drug Profile 92

esketamine hydrochloride-Drug Profile 94

ITI-007-Drug Profile 97

JNJ-42165279-Drug Profile 99

JNJ-42847922-Drug Profile 100

lurasidone hydrochloride-Drug Profile 102

LY-03005-Drug Profile 104

LY-2940094-Drug Profile 105

MAP-4343-Drug Profile 107

MIN-117-Drug Profile 108

miR-135-Drug Profile 109

MSI-195-Drug Profile 110

NLF-NEU-Drug Profile 111

NP-11948-Drug Profile 112

NRX-1074-Drug Profile 113

NSI-189-Drug Profile 114

onabotulinumtoxin A-Drug Profile 116

PH-10-Drug Profile 119

rapastinel-Drug Profile 120

RP-5063-Drug Profile 122

SEP-363856-Drug Profile 123

sirukumab-Drug Profile 124

Small Molecule to Inhibit FKBP51 for Major Depressive Disorder-Drug Profile 127

Small Molecule to Target SLC6A15 for Major Depressive Disorder-Drug Profile 128

Small Molecules to Agonize Kappa Opiod Receptors for Mania and Depressive disorders-Drug Profile 129

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders-Drug Profile 130

Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder-Drug Profile 131

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System-Drug Profile 132

SNG-11-Drug Profile 133

SRX-246-Drug Profile 134

SUVN-911-Drug Profile 136

tedatioxetine hydrobromide-Drug Profile 137

tramadol hydrochloride-Drug Profile 139

trazodone hydrochloride-Drug Profile 140

vortioxetine hydrobromide-Drug Profile 141

VU-0431316-Drug Profile 144

Major Depressive Disorder-Recent Pipeline Updates 145

Major Depressive Disorder-Dormant Projects 189

Major Depressive Disorder-Discontinued Products 196

Major Depressive Disorder-Product Development Milestones 199

Featured News & Press Releases 199

Appendix 207

Methodology 207

Coverage 207

Secondary Research 207

Primary Research 207

Expert Panel Validation 207

Contact Us 207

Disclaimer 208

List of Tables

Number of Products under Development for Major Depressive Disorder, H2 2015 13

Number of Products under Development for Major Depressive Disorder-Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 16

Number of Products under Development by Companies, H2 2015 (Contd..1) 17

Number of Products under Development by Companies, H2 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Late Stage Development, H2 2015 20

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Development, H2 2015 22

Products under Development by Companies, H2 2015 23

Products under Development by Companies, H2 2015 (Contd..1) 24

Products under Development by Companies, H2 2015 (Contd..2) 25

Products under Development by Companies, H2 2015 (Contd..3) 26

Products under Investigation by Universities/Institutes, H2 2015 27

Major Depressive Disorder-Pipeline by Aequus Pharmaceuticals Inc., H2 2015 28

Major Depressive Disorder-Pipeline by Alkermes Plc, H2 2015 29

Major Depressive Disorder-Pipeline by Allergan Plc, H2 2015 30

Major Depressive Disorder-Pipeline by Angelini Group, H2 2015 31

Major Depressive Disorder-Pipeline by Azevan Pharmaceuticals, Inc., H2 2015 32

Major Depressive Disorder-Pipeline by BioCrea GmbH, H2 2015 33

Major Depressive Disorder-Pipeline by Bristol-Myers Squibb Company, H2 2015 34

Major Depressive Disorder-Pipeline by Cerecor Inc., H2 2015 35

Major Depressive Disorder-Pipeline by e-Therapeutics Plc, H2 2015 36

Major Depressive Disorder-Pipeline by Eli Lilly and Company, H2 2015 37

Major Depressive Disorder-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 38

Major Depressive Disorder-Pipeline by GlaxoSmithKline Plc, H2 2015 39

Major Depressive Disorder-Pipeline by H. Lundbeck A/S, H2 2015 40

Major Depressive Disorder-Pipeline by Hua Medicine Ltd., H2 2015 41

Major Depressive Disorder-Pipeline by Intra-Cellular Therapies, Inc., H2 2015 42

Major Depressive Disorder-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 43

Major Depressive Disorder-Pipeline by Johnson & Johnson, H2 2015 44

Major Depressive Disorder-Pipeline by Lead Discovery Center GmbH, H2 2015 45

Major Depressive Disorder-Pipeline by Luye Pharma Group Ltd., H2 2015 46

Major Depressive Disorder-Pipeline by Mapreg S.A.S., H2 2015 47

Major Depressive Disorder-Pipeline by Methylation Sciences Inc., H2 2015 48

Major Depressive Disorder-Pipeline by miCure Therapeutics Ltd., H2 2015 49

Major Depressive Disorder-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 50

Major Depressive Disorder-Pipeline by Naurex, Inc., H2 2015 51

Major Depressive Disorder-Pipeline by Neuralstem, Inc., H2 2015 52

Major Depressive Disorder-Pipeline by nLife Therapeutics, S.L., H2 2015 53

Major Depressive Disorder-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 54

Major Depressive Disorder-Pipeline by Pherin Pharmaceuticals, Inc., H2 2015 55

Major Depressive Disorder-Pipeline by Reviva Pharmaceuticals Inc., H2 2015 56

Major Depressive Disorder-Pipeline by Richter Gedeon Nyrt., H2 2015 57

Major Depressive Disorder-Pipeline by Saniona AB, H2 2015 58

Major Depressive Disorder-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 59

Major Depressive Disorder-Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 60

Major Depressive Disorder-Pipeline by Suven Life Sciences Ltd., H2 2015 61

Major Depressive Disorder-Pipeline by VistaGen Therapeutics , Inc., H2 2015 62

Assessment by Monotherapy Products, H2 2015 63

Assessment by Combination Products, H2 2015 64

Number of Products by Stage and Target, H2 2015 66

Number of Products by Stage and Mechanism of Action, H2 2015 69

Number of Products by Stage and Route of Administration, H2 2015 72

Number of Products by Stage and Molecule Type, H2 2015 74

Major Depressive Disorder Therapeutics-Recent Pipeline Updates, H2 2015 149

Major Depressive Disorder-Dormant Projects, H2 2015 193

Major Depressive Disorder-Dormant Projects (Contd...1), H2 2015 194

Major Depressive Disorder-Dormant Projects (Contd..2), H2 2015 195

Major Depressive Disorder-Dormant Projects (Contd..3), H2 2015 196

Major Depressive Disorder-Dormant Projects (Contd..4), H2 2015 197

Major Depressive Disorder-Dormant Projects (Contd..5), H2 2015 198

Major Depressive Disorder-Dormant Projects (Contd..6), H2 2015 199

Major Depressive Disorder-Discontinued Products, H2 2015 200

Major Depressive Disorder-Discontinued Products (Contd..1), H2 2015 201

Major Depressive Disorder-Discontinued Products (Contd..2), H2 2015 202

List of Figures

Number of Products under Development for Major Depressive Disorder, H2 2015 13

Number of Products under Development for Major Depressive Disorder-Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Products, H2 2015 22

Assessment by Monotherapy Products, H2 2015 63

Number of Products by Top 10 Targets, H2 2015 65

Number of Products by Stage and Top 10 Targets, H2 2015 65

Number of Products by Top 10 Mechanism of Actions, H2 2015 68

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 68

Number of Products by Routes of Administration, H2 2015 71

Number of Products by Stage and Routes of Administration, H2 2015 71

Number of Products by Molecule Types, H2 2015 73

Number of Products by Stage and Molecule Types, H2 2015 73

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aequus Pharmaceuticals Inc.

Alkermes Plc

Allergan Plc

Angelini Group

Azevan Pharmaceuticals, Inc.

BioCrea GmbH

Bristol-Myers Squibb Company

Cerecor Inc.

e-Therapeutics Plc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

H. Lundbeck A/S

Hua Medicine Ltd.

Intra-Cellular Therapies, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

Lead Discovery Center GmbH

Luye Pharma Group Ltd.

Mapreg S.A.S.

Methylation Sciences Inc.

miCure Therapeutics Ltd.

Mitsubishi Tanabe Pharma Corporation

Naurex, Inc.

Neuralstem, Inc.

nLife Therapeutics, S.L.

Otsuka Holdings Co., Ltd.

Pherin Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc.

Suven Life Sciences Ltd.

VistaGen Therapeutics, Inc.

Major Depressive Disorder Therapeutic Products under Development, Key Players in Major Depressive Disorder Therapeutics, Major Depressive Disorder Pipeline Overview, Major Depressive Disorder Pipeline, Major Depressive Disorder Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com